Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Early Rewards for Careful Targeting in Oncology

This article was originally published in Start Up

Executive Summary

Two early-stage cancer deals at the end of last year set a new high for European biotech pre-clinical deal dollars. They also highlighted the growing value, to Big Pharma and Big Biotech, of targeted, well-designed oncology leads, as progress in cancer therapeutics raises the hurdles for new products' potency and selectivity.

You may also be interested in...



Teasing Out Mechanisms of Small-Molecule Kinase Inhibition

Even as kinases remain a popular target in oncology for industry, two recent papers show how much we have yet to learn about how to interfere with these molecules. These most recent laboratory studies help explain the confusing observation that the very act of inhibiting a kinase with a drug can also "prime" phosphorylation of that target, which in some cases can actually enhance tumor activity.

Best of the Blog: Start-Up April 2008

"Best of the Blog" is a monthly column highlighting the best of our free online content at www.windhover.com/blog. In May: cell therapy for Parkinson's, the difficulty of SPACs, Roche buys Piramed, and another boost for microRNA.

Best of the Blog: Start-Up April 2008

"Best of the Blog" is a monthly column highlighting the best of our free online content at www.windhover.com/blog. In May: cell therapy for Parkinson's, the difficulty of SPACs, Roche buys Piramed, and another boost for microRNA.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

MT142639

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel